Name: Cutaneous And Systemic Leishmaniasis Market Size, Share, Industry, Forecast and Outlook (2024-2031)
Brand: DataM Intelligence
SKU: PH1069
Price: 4350 USD
Availability: InStock

Cutaneous And Systemic Leishmaniasis Market Size and Report 2024-2031

Cutaneous And Systemic Leishmaniasis Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Cutaneous And Systemic Leishmaniasis Market is segmented By Drug Class (Pentavalent Antimonials, Anti-fungal Drugs, Antimicrobial / Anti-leishmanial, By Route of Administration (Oral, Topical, Injections, By Indication (Cutaneous leishmaniasis, Mucosal leishmaniasis, Visceral leishmaniasis, By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Size, Share, Outlook, and Opportunity Analysis, 2024-2031</h2>

&nbsp;

<h3>Report Overview</h3>

<blockquote>
The Global &quot;Cutaneous and Systemic Leishmaniasis Market&quot;&nbsp;is expected to grow at a high&nbsp;CAGR&nbsp;during the forecast period (2024-2031).
</blockquote>

Cutaneous leishmaniasis&nbsp;is also known as&nbsp;oriental sore,&nbsp;tropical sore,&nbsp;Aleppo boil,&nbsp;Delhi Boil, or&nbsp;desert boil. It&nbsp;is the most common form of&nbsp;leishmaniasis&nbsp;affecting humans.&nbsp;The cutaneous form presents with skin ulcers. It is a skin infection caused by a&nbsp;single-celled parasite&nbsp;that is&nbsp;transmitted&nbsp;by the bite of a&nbsp;phlebotomine sandfly. There are about twenty species of&nbsp;Leishmania&nbsp;that cause&nbsp;cutaneous&nbsp;leishmaniasis.

<h3>Market Dynamics</h3>

Research and development by prominent manufacturers of this market to introduce new drugs into the market, which are more effective as well as affordable is the key factor driving the global cutaneous and systemic leishmaniasis market. In addition, undergoing clinical trials, which are likely to receive regulatory approval along with increasing government spending on healthcare infrastructure is also estimated to boost the cutaneous &amp; systemic leishmaniasis market. Rising prevalence of cutaneous &amp; systemic leishmaniasis is expected to propel market growth. According to WHO (World Health Organization), around 700,000 to 1 million new cases and some 26,000 to 65,000 deaths occur annually due to cutaneous and systemic leishmaniasis.

However, the treatment for cutaneous and systemic leishmaniasis is very expensive and can cause serious adverse effects such as vomiting, nausea, anorexia, myalgia, abdominal pain, headache, arthralgia, and lethargy and can rarely cause the severe reaction of fatal cardiac arrhythmia. Also, the WHO considers leishmaniasis as one of the main neglected diseases in the world. All these factors are hampering the global cutaneous and systemic leishmaniasis market growth.

<h3>Market Segmentation</h3>

Based on the indication the global Cutaneous and Systemic Leishmaniasis market is broadly segmented as cutaneous leishmaniasis,&nbsp;&nbsp;mucosal leishmaniasis, and visceral leishmaniasis. Among all these visceral leishmaniases accounted for major market share in 2018, and are projected to grow at a high CAGR over the forecast period (2019-2026). Due to increasing incidences of visceral leishmaniasis. Visceral leishmaniasis&nbsp;(VL) is characterized by recurrent bouts of fever, weight loss, enlargement of the spleen and liver, and anemia. According to WHO (World Health Organization), most cases occur in Brazil, East Africa, and South-East Asia, and approximately 50 000 to 90 000 new cases of VL occur worldwide every year.

<h3>Market&nbsp;Geographical Share</h3>

The global Cutaneous and Systemic Leishmaniasis market is segmented into North America, Europe, Asia Pacific, South America, and Middle East &amp; Africa. Latin America and the Asia Pacific accounted for major market share in 2018 and are projected to grow at a high CAGR over the forecast period.&nbsp;It is owing to the high incidence rate of cutaneous &amp; systemic leishmaniasis, in these regions. With a high percentage of disease incidence annually, the demand for drug-based products is estimated to grow significantly. In 2018, globally, the annual rate of cutaneous leishmaniasis (CL) was estimated to be 0.7 to 1.2 million new cases per year. Approximately 75% of cutaneous leishmaniasis is majorly reported in Afghanistan, Algeria, Brazil, Colombia, Costa Rica, Ethiopia, Islamic Republic of Iran, North Sudan, Peru, and the Syrian Arab Republic. Brazil represents approximately 90% of the VL cases in the Latin America region.

<h3>Market Key Players</h3>

Significant players of the global cutaneous and systemic leishmaniasis market are GlaxoSmithKline Plc.; Gilead Sciences, Inc.; Profounda Pharmaceuticals; Knight Therapeutics Inc.; Janssen Global Services, LLC; Albert David Ltd; Jubilant Life Sciences Ltd; Novartis AG; Sanofi A.G; Bristol-Myers Squibb Company, and others. Majority of these prominent players are adopting a few organic and inorganic strategies such as product launches, collaboration, and product agreements, and other key developments to enhance their product portfolio in the global cutaneous and systemic leishmaniasis market.

1.&nbsp;Methodology and Scope

1.1.&nbsp;Research Methodology

1.2.&nbsp;Research Objective and Scope of the Report

2.&nbsp;Market Definition and Overview

3.&nbsp;Executive Summary

3.1. Market Snippet by Drug Class

3.2. Market Snippet by Route of Administration

3.3. Market Snippet by Indication

3.4.&nbsp;Market Snippet by Distribution Channel

3.5.&nbsp;Market Snippet by Region&nbsp;

4.&nbsp;Market Dynamics

4.1. Market Impacting Factors

4.1.1.&nbsp;Drivers

4.1.2. Restraints

4.1.3. Opportunity

4.1.4. Impact Analysis

5.&nbsp;Industry Analysis

5.1.&nbsp;Porter&#39;s Five Forces Analysis

5.2.&nbsp;Supply Chain Analysis

5.3.&nbsp;Pricing Analysis

5.4.&nbsp;Regulatory Analysis

5.5.&nbsp;Patent Analysis

6.&nbsp;By Drug Class

6.1. Introduction

6.1.1.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

6.1.2. Market Attractiveness Index, By Drug Class

6.2.&nbsp;Pentavalent Antimonials

6.2.1. Introduction

6.2.2.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

6.3.&nbsp;&nbsp;Anti-fungal Drugs

6.4.&nbsp;&nbsp;Antimicrobial / Anti-leishmanial

7.&nbsp;By Route of Administration

7.1.&nbsp;Introduction

7.1.1.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

7.1.2. Market Attractiveness Index, By Route of Administration

7.2.&nbsp;Oral

7.2.1. Introduction

7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

7.3.&nbsp;Topical

7.4.&nbsp;Injections

8.&nbsp;By Indication

8.1. Introduction

8.1.1.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

8.1.2. Market Attractiveness Index, By Indication

8.2.&nbsp;Cutaneous leishmaniasis

8.2.1. Introduction

8.2.2.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

8.3.&nbsp;Mucosal leishmaniasis

8.4.&nbsp;Visceral leishmaniasis

9.&nbsp;By Distribution Channel

9.1. Introduction

9.1.1.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9.1.2. Market Attractiveness Index, By Distribution Channel

9.2. Hospital Pharmacies

9.2.1. Introduction

9.2.2.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

9.3. Online Pharmacies

9.4. Retail Pharmacies

10.&nbsp;By Region

10.1.&nbsp;Introduction

10.1.1.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

10.1.2.&nbsp;Market Attractiveness Index, By Region

10.2.&nbsp;North America

10.2.1.&nbsp;Introduction

10.2.2.&nbsp;Key Region-Specific Dynamics

10.2.3.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.2.4.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.2.5.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.2.6.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10.2.7.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.2.7.1.&nbsp;The U.S.

10.2.7.2.&nbsp;Canada

10.2.7.3.&nbsp;Mexico

10.3.&nbsp;&nbsp;Europe

10.3.1.&nbsp;Introduction

10.3.2.&nbsp;Key Region-Specific Dynamics

10.3.3.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.3.4.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.3.5.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.3.6.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10.3.7.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.3.7.1.&nbsp;Germany

10.3.7.2.&nbsp;The U.K.

10.3.7.3.&nbsp;France

10.3.7.4.&nbsp;Italy

10.3.7.5.&nbsp;Spain

10.3.7.6.&nbsp;Rest of Europe

10.4. South America

10.4.1.&nbsp;Introduction

10.4.2.&nbsp;Key Region-Specific Dynamics

10.4.3.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.4.4.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.4.5.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.4.6.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10.4.7.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.4.7.1.&nbsp;Brazil

10.4.7.2.&nbsp;Argentina

10.4.7.3.&nbsp;Rest of South America

10.5. Asia Pacific

10.5.1.&nbsp;Introduction

10.5.2.&nbsp;Key Region-Specific Dynamics

10.5.3.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.5.4.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.5.5.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.5.6.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10.5.7.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.5.7.1.&nbsp;China

10.5.7.2.&nbsp;India

10.5.7.3.&nbsp;Japan

10.5.7.4.&nbsp;Australia

10.5.7.5.&nbsp;Rest of Asia Pacific

10.6.&nbsp;Middle East &amp; Africa

10.6.1.&nbsp;Introduction

10.6.2.&nbsp;Key Region-Specific Dynamics

10.6.3.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.6.4.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.6.5.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.6.6.&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

11.&nbsp; Competitive Landscape

11.1.&nbsp;Competitive Scenario

11.2.&nbsp;Competitor&nbsp;Cutaneous And Systemic Leishmaniasis Strategy Analysis

11.3.&nbsp;Comparative Product Portfolio Analysis

11.4.&nbsp;Market Positioning/Share Analysis

11.5.&nbsp;Mergers and Acquisitions Analysis

12.&nbsp;- Company Profiles

12.1.&nbsp;GlaxoSmithKline Plc.

12.1.1.&nbsp;Company Overview

12.1.2.&nbsp;Product Portfolio and Description

12.1.3.&nbsp;Key Highlights

12.1.4.&nbsp;Financial Overview

12.2.&nbsp;Gilead Sciences, Inc.

12.3.&nbsp;Profounda Pharmaceuticals

12.4.&nbsp;Knight Therapeutics Inc.

12.5.&nbsp;Janssen Global Services, LLC

12.6.&nbsp;Albert David Ltd

12.7.&nbsp;Jubilant Life Sciences Ltd

12.8.&nbsp;Novartis AG

12.9.&nbsp;Sanofi A.G

12.10.&nbsp;Bristol-Myers Squibb Company

13. DataM Intelligence

13.1.&nbsp;Appendix

13.2.&nbsp;About Us and Services

13.3. Contact Us

List of Tables

Table 01.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, 2023, 2027 &amp; 2031 , by drug class, ($million)

Table 02.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, 2023, 2027 &amp; 2031 , by route of administration, ($million)

Table 03.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value 2023, 2027 &amp; 2031 , by distribution channel, ($million)

Table 04.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value 2023, 2027 &amp; 2031 , by indication, ($million)

Table 05.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value 2023, 2027 &amp; 2031 , by region, ($million)

Table 06.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share 2023, 2027 &amp; 2031 (%), by drug class ($million)

Table 07.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, by drug class, 2023&ndash;2031 ($million)

Table 08.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, 2023, 2027 &amp; 2031, by route of administration, ($million)

Table 09.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, by route of administration, 2023&ndash;2031 ($million)

Table 10.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share 2023, 2027 &amp; 2031 (%), by distribution channel ($million)

Table 11.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, by distribution channel, 2023&ndash;2031 ($million)

Table 12.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share 2023, 2027 &amp; 2031 (%), by indication ($million)

Table 13.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, by indication, 2023&ndash;2031 ($million)

Table 14.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share 2023, 2027 &amp; 2031 (%), by region ($million)

Table 15.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, by region, 2023&ndash;2031 ($million)

Table 16.&nbsp;&nbsp;&nbsp;North america cutaneous and systemic leishmaniasis market value, by drug class, 2023&ndash;2031 ($million)

Table 17.&nbsp;&nbsp;&nbsp;North america cutaneous and systemic leishmaniasis market value, by route of administration, 2023&ndash;2031 ($million)

Table 18.&nbsp;&nbsp;&nbsp;North america cutaneous and systemic leishmaniasis market value, by distribution channel, 2023&ndash;2031 ($million)

Table 19.&nbsp;&nbsp;&nbsp;North america cutaneous and systemic leishmaniasis market value, by indication, 2023&ndash;2031 ($million)

Table 20.&nbsp;&nbsp;&nbsp;North america cutaneous and systemic leishmaniasis market value, by country, 2023&ndash;2031 ($million)

Table 21.&nbsp;&nbsp;&nbsp;South america cutaneous and systemic leishmaniasis market value, by drug class, 2023&ndash;2031 ($million)

Table 22.&nbsp;&nbsp;&nbsp;South america cutaneous and systemic leishmaniasis market value, by route of administration, 2023&ndash;2031 ($million)

Table 23.&nbsp;&nbsp;&nbsp;South america cutaneous and systemic leishmaniasis market value, by distribution channel, 2023&ndash;2031 ($million)

Table 24.&nbsp;&nbsp;&nbsp;South america cutaneous and systemic leishmaniasis market value, by indication, 2023&ndash;2031 ($million)

Table 25.&nbsp;&nbsp;&nbsp;South america cutaneous and systemic leishmaniasis market value, by country, 2023&ndash;2031 ($million)

Table 26.&nbsp;&nbsp;&nbsp;Europe cutaneous and systemic leishmaniasis market value, by drug class, 2023&ndash;2031 ($million)

Table 27.&nbsp;&nbsp;&nbsp;Europe cutaneous and systemic leishmaniasis market value, by route of administration, 2023&ndash;2031 ($million)

Table 28.&nbsp;&nbsp;&nbsp;Europe cutaneous and systemic leishmaniasis market value, by distribution channel, 2023&ndash;2031 ($million)

Table 29.&nbsp;&nbsp;&nbsp;Europe cutaneous and systemic leishmaniasis market value, by indication, 2023&ndash;2031 ($million)

Table 30.&nbsp;&nbsp;&nbsp;Europe cutaneous and systemic leishmaniasis market value, by country, 2023&ndash;2031 ($million)

Table 31.&nbsp;&nbsp;&nbsp;Asia pacific cutaneous and systemic leishmaniasis market value, by drug class, 2023&ndash;2031 ($million)

Table 32.&nbsp;&nbsp;&nbsp;Asia pacific cutaneous and systemic leishmaniasis market value, by route of administration, 2023&ndash;2031 ($million)

Table 33.&nbsp;&nbsp;&nbsp;Asia pacific cutaneous and systemic leishmaniasis market value, by distribution channel, 2023&ndash;2031 ($million)

Table 34.&nbsp;&nbsp;&nbsp;Asia pacific cutaneous and systemic leishmaniasis market value, by indication, 2023&ndash;2031 ($million)

Table 35.&nbsp;&nbsp;&nbsp;Asia pacific cutaneous and systemic leishmaniasis market value, by country, 2023&ndash;2031 ($million)

Table 36.&nbsp;&nbsp;&nbsp;Middle east &amp; africa cutaneous and systemic leishmaniasis market value, by drug class, 2023&ndash;2031 ($million)

Table 37.&nbsp;&nbsp;&nbsp;Middle east &amp; africa cutaneous and systemic leishmaniasis market value, by route of administration, 2023&ndash;2031 ($million)

Table 38.&nbsp;&nbsp;&nbsp;Middle east &amp; africa cutaneous and systemic leishmaniasis market value, by distribution channel, 2023&ndash;2031 ($million)

Table 39.&nbsp;&nbsp;&nbsp;Middle east &amp; africa cutaneous and systemic leishmaniasis market value, by indication, 2023&ndash;2031 ($million)

Table 40.&nbsp;&nbsp;&nbsp;Gilead sciences, inc: overview

Table 41.&nbsp;&nbsp;&nbsp;Gilead sciences, inc: product portfolio

Table 42.&nbsp;&nbsp;&nbsp;Gilead sciences, inc: key developments

Table 43.&nbsp;&nbsp;&nbsp;Profounda pharmaceuticals: overview

Table 44.&nbsp;&nbsp;&nbsp;Profounda pharmaceuticals: product portfolio

Table 45.&nbsp;&nbsp;&nbsp;Profounda pharmaceuticals: key developments

Table 46.&nbsp;&nbsp;&nbsp;Knight therapeutics inc: overview

Table 47.&nbsp;&nbsp;&nbsp;Knight therapeutics inc: product portfolio

Table 48.&nbsp;&nbsp;&nbsp;Knight therapeutics inc: key developments

Table 49.&nbsp;&nbsp;&nbsp;Janssen global services: overview

Table 50.&nbsp;&nbsp;&nbsp;Janssen global services: product portfolio

Table 51.&nbsp;&nbsp;&nbsp;Janssen global services: key developments

Table 52.&nbsp;&nbsp;&nbsp;Albert david ltd: overview

Table 53.&nbsp;&nbsp;&nbsp;Albert david ltd: product portfolio

Table 54.&nbsp;&nbsp;&nbsp;Albert david ltd: key developments

Table 55.&nbsp;&nbsp;&nbsp;Jubilant life sciences ltd: overview

Table 56.&nbsp;&nbsp;&nbsp;Jubilant life sciences ltd: product portfolio

Table 57.&nbsp;&nbsp;&nbsp;Jubilant life sciences ltd: key developments

Table 58.&nbsp;&nbsp;&nbsp;Glaxosmithkline plc.: overview

Table 59.&nbsp;&nbsp;&nbsp;Glaxosmithkline plc.: product portfolio

Table 60.&nbsp;&nbsp;&nbsp;Glaxosmithkline plc.: kg: key developments

Table 61.&nbsp;&nbsp;&nbsp;Novartis ag.: overview

Table 62.&nbsp;&nbsp;&nbsp;Novartis ag.: product portfolio

Table 63.&nbsp;&nbsp;&nbsp;Novartis ag.: key developments

Table 64.&nbsp;&nbsp;&nbsp;Sanofi a.g.: overview

Table 65.&nbsp;&nbsp;&nbsp;Sanofi a.g.: product portfolio

Table 66.&nbsp;&nbsp;&nbsp;Sanofi a.g.: key developments

Table 67.&nbsp;&nbsp;&nbsp;Bristol-myers squibb company: overview

Table 68.&nbsp;&nbsp;&nbsp;Bristol-myers squibb company: product portfolio

Table 69.&nbsp;&nbsp;&nbsp;Bristol-myers squibb company: key developments

&nbsp;

List of figures

Figure 01.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share, 2023 &amp; 2031 (%), by drug class

Figure 02.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share, 2023 &amp; 2031 (%), by route of administration

Figure 03.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share, 2023 &amp; 2031 (%), by distribution channel

Figure 04.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share, 2023 &amp; 2031 (%), by indication

Figure 05.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market share, 2023 &amp; 2031 (%), by region

Figure 06.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market value, 2021 - 2029 and year on year growth

Figure 07.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market year on year growth 2023 to 2031 (%), by drug class

Figure 08&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by pentavalent antimonials, 2023&ndash;2031 ($million)

Figure 09&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by anti-fungal drugs, 2023&ndash;2031 ($million)

Figure 10&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by antimicrobial / anti-leishmanial, 2023&ndash;2031 ($million)

Figure 11.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market year on year growth 2023 to 2031 (%), by route of administration

Figure 12&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by oral, 2023&ndash;2031 ($million)

Figure 13&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by injection, 2023&ndash;2031 ($million)

Figure 14&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by topical, 2023&ndash;2031 ($million)

Figure 15.&nbsp;&nbsp;&nbsp;Global cutaneous and systemic leishmaniasis market year on year growth 2023 to 2031 (%), by distribution channel

Figure 16&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by hospital pharmacies, 2023&ndash;2031 ($million)

Figure 17&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by online pharmacies, 2023&ndash;2031 ($million)

Figure 18&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by retail pharmacies, 2023&ndash;2031 ($million)

Figure 19&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market year on year growth 2023 to 2031 (%), by indication

Figure 20&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by cutaneous leishmaniasis, 2023&ndash;2031 ($million)

Figure 21&nbsp;&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by mucosal leishmaniasis, 2023&ndash;2031 ($million)

Figure 22&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market value, by visceral leishmaniasis, 2023&ndash;2031 ($million)

Figure 22&nbsp;&nbsp;&nbsp;global cutaneous and systemic leishmaniasis market year on year growth 2023 to 2031 (%), by region

Figure 23&nbsp;&nbsp;&nbsp;&nbsp;north america cutaneous and systemic leishmaniasis market value, 2023&ndash;2031 ($million)

Figure 24&nbsp;&nbsp;&nbsp;&nbsp;north america cutaneous and systemic leishmaniasis market share (%), by product drug class, 2023&ndash;2031 ($million)

Figure 25&nbsp;&nbsp;&nbsp;&nbsp;north america cutaneous and systemic leishmaniasis market share (%), by distribution channel, 2023&ndash;2031 ($million)

Figure 26&nbsp;&nbsp;&nbsp;&nbsp;north america cutaneous and systemic leishmaniasis market share (%), by indication, 2023&ndash;2031 ($million)

Figure 27&nbsp;&nbsp;&nbsp;&nbsp;north america cutaneous and systemic leishmaniasis market share (%), by countries, 2023&ndash;2031 ($million)

Figure 28&nbsp;&nbsp;&nbsp;south america cutaneous and systemic leishmaniasis market value, 2023&ndash;2031 ($million)

Figure 29&nbsp;&nbsp;&nbsp;&nbsp;south america cutaneous and systemic leishmaniasis market share (%), by product drug class, 2023&ndash;2031 ($million)

Figure 30&nbsp;&nbsp;&nbsp;south america cutaneous and systemic leishmaniasis market share (%), by distribution channel, 2023&ndash;2031 ($million)

Figure 31&nbsp;&nbsp;&nbsp;&nbsp;south america cutaneous and systemic leishmaniasis market share (%), by indication, 2023&ndash;2031 ($million)

Figure 32&nbsp;&nbsp;&nbsp;&nbsp;south america cutaneous and systemic leishmaniasis market share (%), by countries, 2023&ndash;2031 ($million)

Figure 33&nbsp;&nbsp;&nbsp;&nbsp;europe cutaneous and systemic leishmaniasis market value, 2023&ndash;2031 ($million)

Figure 34&nbsp;&nbsp;europe cutaneous and systemic leishmaniasis market share (%), by product drug class, 2023&ndash;2031 ($million)

Figure 35&nbsp;&nbsp;&nbsp;&nbsp;europe cutaneous and systemic leishmaniasis market share (%), by distribution channel, 2023&ndash;2031 ($million)

Figure 36&nbsp;&nbsp;europe cutaneous and systemic leishmaniasis market share (%), by indication, 2023&ndash;2031 ($million)

Figure 37&nbsp;&nbsp;&nbsp;europe cutaneous and systemic leishmaniasis market share (%), by countries, 2023&ndash;2031 ($million)

Figure 38&nbsp;&nbsp;&nbsp;asia pacific cutaneous and systemic leishmaniasis market value, 2023&ndash;2031 ($million)

Figure 39&nbsp;&nbsp;&nbsp;&nbsp;asia pacific cutaneous and systemic leishmaniasis market share (%), by product drug class, 2023&ndash;2031 ($million)

Figure 40&nbsp;&nbsp;&nbsp;&nbsp;asia pacific cutaneous and systemic leishmaniasis market share (%), by distribution channel, 2023&ndash;2031 ($million)

Figure 41&nbsp;&nbsp;&nbsp;&nbsp;asia pacific cutaneous and systemic leishmaniasis market share (%), by indication, 2023&ndash;2031 ($million)

Figure 42&nbsp;&nbsp;&nbsp;&nbsp;asia pacific cutaneous and systemic leishmaniasis market share (%), by countries, 2023&ndash;2031 ($million)

Figure 43&nbsp;&nbsp;&nbsp;middle east and africa cutaneous and systemic leishmaniasis market value, 2023&ndash;2031 ($million)

Figure 44&nbsp;&nbsp;&nbsp;&nbsp;middle east and africa cutaneous and systemic leishmaniasis market share (%), by product drug class, 2023&ndash;2031 ($million)

Figure 45&nbsp;&nbsp;&nbsp;&nbsp;middle east and africa cutaneous and systemic leishmaniasis market share (%), by distribution channel, 2023&ndash;2031 ($million)

Figure 46&nbsp;&nbsp;&nbsp;&nbsp;middle east and africa cutaneous and systemic leishmaniasis market share (%), by indication, 2023&ndash;2031 ($million)

Figure 47.&nbsp;&nbsp;&nbsp;Gilead sciences, inc: financials

Figure 48.&nbsp;&nbsp;&nbsp;Profounda pharmaceuticals: financials

Figure 49.&nbsp;&nbsp;&nbsp;Knight therapeutics inc: financials

Figure 50&nbsp;&nbsp;&nbsp;janssen global services: financials

Figure 51.&nbsp;&nbsp;&nbsp;Albert david ltd: financials

Figure 52.&nbsp;&nbsp;&nbsp;Jubilant life sciences ltd: financials

Figure 53.&nbsp;&nbsp;&nbsp; Glaxosmithkline plc.: financials

Figure 54.&nbsp;&nbsp;&nbsp;Novartis ag.: financials

Figure 55.&nbsp;&nbsp;&nbsp;Sanofi a.g.: financials

Figure 56.&nbsp;&nbsp;&nbsp;Bristol-myers squibb company: financials

Cutaneous And Systemic Leishmaniasis Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Size, Share, Industry, and Outlook (2023-2030)

Published: 2023 November 13

Starting from

Cutaneous Lupus Erythematosus Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Published: 2023 December 14

Starting from

Cutaneous Squamous Cell Carcinoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 March 05

Starting from